Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm-Reference-Cited by-同舟云学术

Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm

Published:2023-01 Issue: Volume:15 Page:175883592311754
ISSN:1758-8359
Container-title:Therapeutic Advances in Medical Oncology
language:en
Short-container-title:Ther Adv Med Oncol

Author:

Yang Charlie¹,Brezden-Masley Christine²^ORCID,Joy Anil Abraham³,Sehdev Sandeep⁴^ORCID,Modi Shanu⁵,Simmons Christine⁶^ORCID,Henning Jan-Willem⁷

Affiliation:

1. Tom Baker Cancer Centre, University of Calgary, 1331 29 Street NW, Calgary, AB T2N 4N2, Canada

2. Sinai Health System, Mountain Sinai Hospital, University of Toronto, Toronto, ON, Canada

3. Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada

4. The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada

5. Memorial Sloan Kettering Cancer Center, New York, NY, USA

6. BC Cancer Agency – Vancouver Centre, University of British Columbia, Vancouver, BC, Canada

7. Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada

Abstract

The results of the Phase III DESTINY-Breast04 trial of trastuzumab deruxtecan (T-DXd) are leading to a shift in both the classification and treatment of human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. In this trial, T-DXd was associated with a substantial survival benefit among patients with hormone receptor-positive and hormone receptor-negative disease and low expression of HER2, a biomarker previously considered unactionable in this treatment setting. Herein, we discuss the evolving therapeutic pathway for HER2-low disease, ongoing clinical trials, and the potential challenges and evidence gaps arising with treatment of this patient population.

Funder

AstraZeneca Canada

Publisher

SAGE Publications

Subject

Oncology

Link

http://journals.sagepub.com/doi/pdf/10.1177/17588359231175440

Reference96 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Systemic therapy for metastatic HER2-positive breast cancer

3. Canadian Cancer Society. Survival statistics for breast cancer. Available at: https://cancer.ca/en/cancer-information/cancer-types/breast/prognosis-and-survival/survival-statistics. (2022, accessed 4 October 2022).

4. Survival in Women with De Novo Metastatic Breast Cancer: A Comparison of Real-World Evidence from a Publicly-Funded Canadian Province and the United States by Insurance Status

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring a Novel Approach to Spare Classic Chemotherapy in HER2-Low, ER-Positive Breast Cancer Based on Trastuzumab Deruxtecan Combined with Endocrine Therapy;Oncology and Therapy;2024-06-28

2. Advancing HER2-low breast cancer management: enhancing diagnosis and treatment strategies;Radiology and Oncology;2024-06-01

3. Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial;Expert Review of Pharmacoeconomics & Outcomes Research;2023-12